MargaretMacyMD

Pediatric Hematology & Oncology • Aurora, CO

Associate Professor of Pediatrics, University Colorado

Join to view full profile

Dr. Macy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Macy's full profile

Already have an account?

Office
13123 E 16th Ave
Aurora, CO 80045
Phone+1 720-777-1234
Is this information wrong?

Education & Training

University of ColoradoFellowship, Pediatric Hematology/Oncology, 2005 - 2008
University of ColoradoResidency, Pediatrics, 2002 - 2005
Case Western Reserve University School of MedicineClass of 2002

Certifications & Licensure

CO State Medical License 2004 - 2025
MT State Medical License 2021 - 2025
NM State Medical License 2021 - 2025
WY State Medical License 2021 - 2024
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Fellow (FAAP) American Academy of Pediatrics

Clinical Trials

Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients Start of enrollment: 2009 Aug 01
Completed
Phase 2
The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors Start of enrollment: 2010 Jun 28
Terminated
Not Applicable
Neuroblastoma Biology Study Start of enrollment: 2011 Jul 01
Recruiting
Expanded Access Protocol Using 131I-MIBG
Available
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma Start of enrollment: 2013 Feb 04
Active, not recruiting
Phase 1
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16
Active, not recruiting
Phase 1
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Start of enrollment: 2014 Jul 01
Completed
Phase 2
Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma Start of enrollment: 2015 Oct 08
Active, not recruiting
Phase 1
SF1126 for Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2015 Jul 09
Terminated
Phase 1
The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study Start of enrollment: 2015 Oct 01
Active, not recruiting
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2015 Oct 21
Completed
Phase 1
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma Start of enrollment: 2016 Jan 07
Completed
Phase 1
Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Start of enrollment: 2016 Feb 01
Completed
Phase 1
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options Start of enrollment: 2016 May 03
Active, not recruiting
Phase 1, Phase 2
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma Start of enrollment: 2016 Mar 01
Completed
Phase 1, Phase 2
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia Start of enrollment: 2015 Dec 01
Withdrawn
Phase 1
Neuroblastoma Precision Trial Start of enrollment: 2016 Aug 22
Active, not recruiting
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) Start of enrollment: 2017 Sep 05
Active, not recruiting
Phase 1
A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects Start of enrollment: 2019 Oct 21
Recruiting
Phase 2
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08
Active, not recruiting
Phase 2
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2019 May 17
Completed
Phase 1
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Start of enrollment: 2020 Mar 12
Recruiting
Phase 1, Phase 2
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor Start of enrollment: 2020 Jan 22
Active, not recruiting
Phase 1, Phase 2
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma Start of enrollment: 2020 Mar 04
Terminated
Phase 1, Phase 2
MIBG With Dinutuximab +/- Vorinostat Start of enrollment: 2018 Sep 12
Active, not recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Clinical Targeted Next-Generation Panel Sequencing RevealsAmplification Is a Poor Prognostic Factor in Osteosarcoma.
Amanda E Marinoff, Liam F Spurr, Christina Fong, Yvonne Y Li, Suzanne J Forrest, Abigail Ward, Duong Doan, Laura Corson, Audrey Mauguen, Navin Pinto, Luke Maese, Susan...> ;JCO Precision Oncology. 2023 Mar 1
9 citations
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macro...
Benjamin J Lerman, Yimei Li, Cecilia Carlowicz, Meaghan Granger, Thomas Cash, Arhanti Sadanand, Katherine Somers, Aeesha Ranavaya, Brian D Weiss, Michelle Choe, Jennif...> ;Journal of Clinical Oncology. 2023 Jan 20
2 citations
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National...
Julie R Park, Judith G Villablanca, Barbara Hero, Brian H Kushner, Keith Wheatley, Klaus H Beiske, Ruth L Ladenstein, Sylvain Baruchel, Margaret E Macy, Lucas Moreno, ...> ;Cancer. 2022 Nov 1
5 citations
Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer.
Lorena Lazo De La Vega, Hannah Comeau, Sarah Sallan, Alyaa Al-Ibraheemi, Hersh Gupta, Yvonne Y Li, Harrison K Tsai, Wenjun Kang, Abigail Ward, Alanna J Church, AeRang ...> ;JCO Precision Oncology. 2022 Nov 1
35 citations
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
Ami V Desai, Giles W Robinson, Karen Gauvain, Ellen M Basu, Margaret E Macy, Luke Maese, Nicholas S Whipple, Amit J Sabnis, Jennifer H Foster, Suzanne Shusterman, Jane...> ;Neuro-Oncology. 2022 Oct 3
11 citations
Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial.
David M Loeb, Daniel A Morgenstern, Yvan Samson, Anne Uyttebroeck, Chuhl Joo Lyu, An Van Damme, Karsten Nysom, Margaret E Macy, Alexandra P Zorzi, Julia Xiong, Petra P...> ;Cancer Immunology, Immunotherapy. 2022 Oct 1
25 citations
High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes.
Steven G DuBois, Margaret E Macy, Tara O Henderson> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2022 Apr 1
8 citations
Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor.
Jaclyn Schienda, Alanna J Church, Laura B Corson, Brennan Decker, Catherine M Clinton, Danielle K Manning, Alma Imamovic-Tuco, Deirdre Reidy, Gianna R Strand, Mark A A...> ;JCO Precision Oncology. 2021 Jan 1
20 citations
Opportunities and Challenges in Drug Development for Pediatric Cancers.
Theodore W. Laetsch, Steven G. DuBois, Julia Glade Bender, Margaret E. Macy, Lucas Moreno> ;Cancer Discovery. 2021 Mar 1
15 citations
Experience with ponatinib in paediatric patients with leukaemia.
Jenna Rossoff, Van Huynh, Rachel E. Rau, Margaret E. Macy, Maria Luisa Sulis, Kirk R. Schultz, Michael J. Burke, Uma H. Athale, Maureen M. O'Brien, John Gregory, Inge ...> ;British Journal of Haematology. 2020 Jan 24
153 citations
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim anal...
Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, Lynley V. Marshall, Catherine Vezina, Alberto S. Pappo, Theodore W. Laetsch, Antonio Sergio Petrilli, Martin Ebing...> ;The Lancet. Oncology. 2020 Jan 1
10 citations
Bevacizumab in the treatment of radiation injury for children with central nervous system tumors
Nathan Dahl, Arthur K. Liu, Nicholas K. Foreman, Melissa Widener, Laura Z. Fenton, Margaret E. Macy> ;Child's Nervous System. 2019 Jul 31
4 citations
Central Nervous System Involvement of Rhabdomyosarcoma: A Single Institution Experience.
Daniel C. Moreira, Margaret E. Macy, Carrye R. Cost, Brian Greffe, Timothy P. Garrington> ;Journal of Pediatric Hematology/oncology. 2019 Mar 1
48 citations
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Steven G. DuBois, Yael P. Mosse, Elizabeth Fox, Rachel A. Kudgus, Joel M. Reid, Renee M. McGovern, S. Groshen, Rochelle Bagatell, John M. Maris, Clare J. Twist, Kelly ...> ;Clinical Cancer Research. 2018 Dec 15
31 citations
Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
Holly L Pacenta, Margaret E. Macy> ;Drug Design, Development and Therapy. 2018 Oct 23
6 citations
A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.
Peter E. Manley, Tanya M. Trippett, Amy Smith, Margaret E. Macy, Sarah Leary, Jessica Boklan, Kenneth J. Cohen, Stewart Goldman, Lindsay Kilburn, Girish Dhall, Jeanne ...> ;Pediatric Blood & Cancer. 2018 Sep 1
27 citations
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial
Navin Pinto, Steven G. DuBois, Araz Marachelian, Scott J. Diede, Agne Taraseviciute, Julia L. Glade Bender, Denice D. Tsao-Wei, Susan Groshen, Joel M. Reid, Daphne A. ...> ;Pediatric Blood & Cancer. 2018 Jul 1
22 citations
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
Lia Gore, Timothy J. Triche, Jason E. Farrar, Daniel H. Wai, Christophe Legendre, Gerald C. Gooden, Winnie S. Liang, John D. Carpten, David W. Lee, Frank Alvaro, Marga...> ;Clinical Epigenetics. 2017 Oct 5
55 citations
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or my...
Todd Cooper, Edward Allan R. Sison, Sharyn D. Baker, Lie Li, Amina Ahmed, Tanya M. Trippett, Lia Gore, Margaret E. Macy, Aru Narendran, Keith J. August, Michael J. Abs...> ;Pediatric Blood & Cancer. 2017 Aug 1
13 citations
A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high‐grade astrocytomas: A Pediatric Oncology ...
Margaret E. Macy, Mark W. Kieran, Susan N. Chi, Kenneth J. Cohen, Tobey J. MacDonald, Amy Smith, Michael Etzl, Michele C. Kuei, Andrew M. Donson, Lia Gore, Jennifer Di...> ;Pediatric Blood & Cancer. 2017 May 24
18 citations
Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours.
Didier Frappaz, Sara M. Federico, Andrew D.J. Pearson, Lia Gore, Margaret E. Macy, Steven G. DuBois, Isabelle Aerts, Robert Iannone, Ryan Geschwindt, Arne van Schanke,...> ;European Journal of Cancer. 2016 Jul 1
18 citations
Non-Rhabdomyosarcoma Soft Tissue Sarcomas in Children: A Surveillance, Epidemiology, and End Results Analysis Validating COG Risk Stratifications
Timothy V. Waxweiler, Chad G. Rusthoven, Michelle S. Proper, Carrye R. Cost, Nicholas G. Cost, Nathan Donaldson, Timothy P. Garrington, Brian Greffe, Travis C. Heare, ...> ;International Journal of Radiation Oncology, Biology, Physics. 2015 Jun 1
21 citations
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.
Robin E. Norris, Suzanne Shusterman, Lia Gore, Jodi A. Muscal, Margaret E. Macy, Elizabeth Fox, Noah Berkowitz, Aby Buchbinder, Rochelle Bagatell> ;Pediatric Blood & Cancer. 2014 Oct 1
4 citations
The relationship between thyroid dose and diagnosis of primary hypothyroidism in pediatric brain tumor patients receiving craniospinal irradiation
Christine Lauro, Margaret E. Macy, Philip Zeitler, Jennifer Backus, Pamela Mettler, Nicholas K. Foreman, Arthur K. Liu> ;Journal of Pediatric Endocrinology & Metabolism. 2014 Mar 1
19 citations
A Multicenter, First-in-Pediatrics, Phase 1, Pharmacokinetic and Pharmacodynamic Study of Ridaforolimus in Patients with Refractory Solid Tumors
Lia Gore, Tanya M. Trippett, Howard M. Katzenstein, Jessica Boklan, Aru Narendran, Amy Smith, Margaret E. Macy, Katherine Rolla, Narayana Narashimhan, Rachel M. Squill...> ;Clinical Cancer Research. 2013 Jul 1
Join now to see all

Journal Articles

Phase 2 Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Margaret Macy, MD, Clinical Cancer Research

Professional Memberships

American Academy of Pediatrics - AAP
Fellow
American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Children's Hospital ColoradoAurora, Colorado

MargaretMacyMD

Dr. Macy is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Professional Memberships

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.